Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response
- PMID: 21508735
- DOI: 10.1097/RTI.0b013e3182128704
Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response
Abstract
Positron emission tomography (PET)/computed tomographic scanning, using 18F-2-deoxy-D-glucose, complements conventional imaging evaluation of patients with lung cancer. The strength of PET scanning lies in the detection of nodal and extrathoracic metastases. PET scanning is also currently being studied in the assessment of prognosis and therapeutic response and has the potential to alter management of oncologic patients. This review will discuss the role of PET/computed tomographic scanning in the diagnosis, staging, and evaluation of prognosis and treatment response in patients with lung cancer.
Similar articles
-
Positron emission tomography imaging in nonsmall-cell lung cancer.Cancer. 2007 Nov 15;110(10):2155-68. doi: 10.1002/cncr.23051. Cancer. 2007. PMID: 17896784
-
Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?Chest. 2004 Sep;126(3):755-60. doi: 10.1378/chest.126.3.755. Chest. 2004. PMID: 15364753
-
Value of FDG PET in the management of NSCLC.Lung Cancer. 2004 Aug;45 Suppl 2:S75-8. doi: 10.1016/j.lungcan.2004.07.989. Lung Cancer. 2004. PMID: 15552785 Review.
-
Prognosis and reevaluation of lung cancer by positron emission tomography imaging.Proc Am Thorac Soc. 2009 Apr 15;6(2):171-9. doi: 10.1513/pats.200806-059LC. Proc Am Thorac Soc. 2009. PMID: 19349485 Review.
-
Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.Int J Cancer. 2013 Jan 15;132(2):E37-47. doi: 10.1002/ijc.27779. Epub 2012 Sep 1. Int J Cancer. 2013. PMID: 22890912
Cited by
-
PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.Cancers (Basel). 2022 May 29;14(11):2689. doi: 10.3390/cancers14112689. Cancers (Basel). 2022. PMID: 35681669 Free PMC article. Review.
-
Management of malignant pleural effusion.Lung. 2013 Apr;191(2):165-75. doi: 10.1007/s00408-012-9445-1. Epub 2013 Jan 13. Lung. 2013. PMID: 23315213 Review.
-
PET/CT used in the evaluation of pulmonary nodules suspicious for lung cancer in regions where infectious lung disease is endemic: to be or not to be?Radiol Bras. 2016 May-Jun;49(3):199. doi: 10.1590/0100-3984.2016.49.3.ce1. Radiol Bras. 2016. PMID: 27403022 Free PMC article. No abstract available.
-
PET/CT in the staging of the non-small-cell lung cancer.J Biomed Biotechnol. 2012;2012:783739. doi: 10.1155/2012/783739. Epub 2012 Mar 7. J Biomed Biotechnol. 2012. PMID: 22577296 Free PMC article. Review.
-
Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients.EJNMMI Res. 2019 Feb 7;9(1):14. doi: 10.1186/s13550-019-0481-1. EJNMMI Res. 2019. PMID: 30734113 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical